9 New ‘Independent’ Advisers to CDC Publicly Promoted Vaccines or Took Money From Pharma — or Both


by Brenda Baletti, Ph.D., Childrens Health Defense:

After struggling for months to fill seats on the Centers for Disease Control and Prevention’s vaccine advisory committee, the U.S. Department of Health and Human Services announced nine new appointees. All have financial ties to vaccine makers or have publicly promoted COVID-19, RSV and HPV vaccines — or both.

TRUTH LIVES on at https://sgtreport.tv/

The U.S. Department of Health and Human Services (HHS) in mid-February appointed the new members to the Advisory Committee on Immunization Practices (ACIP), which shapes U.S. vaccine policy.

Commenting on the new appointments, Children’s Health Defense (CHD) President Mary Holland said:

“ACIP has long been a rubber stamp for any and all vaccines Big Pharma wants to push. But the brazenness of the HHS-Big Pharma fusion has never been so much on display.

“The only silver lining in this grotesque display is that more and more people are waking up to the reality that ACIP has nothing to do with health and everything to do with profit.”

The ACIP is described as an independentnonfederal expert body made up of professionals with clinical, scientific and public health expertise. The committee decides which vaccines should be recommended to the public, who should take them and how often — recommendations the CDC typically rubber stamps.

This external advisory committee includes a chair, an executive secretary, and 15 voting members — 14 medical experts and a lay member representing consumers.

It also includes a non-voting body that offers input composed of eight ex officio members from other federal health departments and liaison representatives from health-related professional organizations like the American Association of Pediatrics.

However, when the committee convened last week to make its spring recommendations, it was missing so many voting members that it lacked a quorum. Vacant committee spaces on the “independent” committee had to be temporarily filled by government employees — ex officio members can be sworn in as temporary voting members.

Over the last year, HHS struggled to fill eight vacancies. An additional four members will be needed when existing members’ four-year terms are up at the end of June.

As seats on the committee sat unfilled, industry news sites like StatNews suggested the committee “appears to be atrophying” and Medriva said there is an “unprecedented lack of expertise in the committee.”

When HHS finally announced the new members to fill the vacancies, it was also reported the new members would be filling spots at last week’s meeting. However, they had not yet taken their positions at the time the meeting occurred on Feb. 28-29.

A CDC spokesperson confirmed to The Defender that nine members have been appointed to the committee, including Dr. Helen Keipp Talbot, an infectious diseases researcher at Vanderbilt University who previously served on the committee from 2018 through 2022 and will rejoin the committee to serve as chair.

Members typically are not eligible for reappointment, but in Talbot’s case, the HHS provided a waiver to that existing policy.

In addition to Talbot, four members will begin their tenure immediately upon submission of paperwork. These include Dr. Denise Jamieson, dean of the University of Iowa Carver College of Medicine; Dr. Yvonne Maldonado, a professor of pediatrics at Stanford University; Dr. Robert Schechter, a medical officer with the California Department of Public Health; and Dr. Albert Shaw, an infectious diseases professor at the Yale School of Medicine.

The other appointees will begin on July 1. They include Dr. Edwin Asturias, a pediatric infectious diseases specialist at the Colorado School of Public Health; Noel Brewer, Ph.D., a professor of health behavior at the University of North Carolina; Dr. Helen Chu, an infectious diseases specialist at the University of Washington; and Dr. George Kuchel, a professor of geriatric medicine at the University of Connecticut.

All nine appointees will serve four-year terms.

“Stringent measures and rigorous screening” are reportedly used to avoid the committee members having “real or apparent” conflicts of interest.

However, all of the new appointees except for the public member have received grant funding or consulting fees from major pharmaceutical companies, including vaccine makers like Pfizer, Moderna and Merck, or have worked for HHS or on recent HHS grants developing or testing vaccines or investigating how to improve vaccine uptake.

Read More @ ChildrensHealthDefense.org